Treatment
Monoclonal antibody clinical trials
We’re tracking 155 recruiting studies that include Monoclonal antibody, each written for real people, not researchers, below.
Recruiting studies
- NCT05013632Recruiting
COVID-19 pregnancy medicine registry for expecting or recent mothers
This study is a registry that collects information about COVID-19 during pregnancy, including what treatments were used and pregnancy outcomes. It may help doctors better understand the safety and effects of COVID-19 medicines in pregnancy.
Los Angeles, CaliforniaAges 18–50 - NCT05041907RecruitingPhase 2
Testing an antiviral’s effects in early COVID-19
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
Minas GeraisAges 18–60 - NCT05182957RecruitingPhase 2
Study of anti-PD-1, lenalidomide, and azacitidine for PTCL
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
Suzhou, JiangsuAges 18 years+ - NCT05231122RecruitingPhase 2
Pembrolizumab and bevacizumab for recurrent ovarian cancer
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Buffalo, New YorkAges 18 years+ - NCT05290194RecruitingPhase 2
New metastatic nasopharyngeal cancer trial with radiotherapy and PD-1
This trial studies whether adding targeted radiotherapy (SBRT) to PD-1 immunotherapy plus capecitabine can improve outcomes for people with newly diagnosed metastatic nasopharyngeal cancer. You may be eligible if your cancer has responded at least to “stable disease” after an initial chemo-immunotherapy course.
Zhuhai, GuangdongAges 18–70 - NCT05300035RecruitingPhase 2
HIV treatment add-on antibodies during early infection
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
BobignyAges 18–70 - NCT05392413Recruiting
Predicting who benefits from PD-1 antibody for esophageal cancer
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
GuangzhouAges 18–75 - NCT05713994Recruiting
Liver cancer treatments together for unresectable liver tumors
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
Quanzhou, FujianAges 18 years+ - NCT05717738Recruiting
Immunotherapy plus targeted drugs after TACE for liver cancer
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
Quanzhou, FujianAges 18 years+ - NCT05886439RecruitingPhase 1/Phase 2
Study drug plus PD-1 or PD-L1 for lung cancer
This Phase 1/2 trial tests a new treatment called LK101 combined with a PD-1 or PD-L1 antibody for advanced lung cancer. It may help shrink tumors and improve control of the disease, especially after prior anti–PD-1/PD-L1 treatment has stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05914389RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for colon cancer
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
Hangzhou, ZhejiangAges 18–75 - NCT05941507RecruitingPhase 1/Phase 2
TROP2 antibody drug with anti–PD-1 for advanced solid tumors
This early-phase study tests an antibody-drug (an ADC) that targets TROP2, given by itself and together with an anti–PD-1 medicine. It’s for people with advanced solid cancers that have not responded to standard treatments, aiming to shrink tumors and improve control of the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06008691Recruiting
Study of newer antibodies for B-cell lymphoma in Italy
This study watches how newer monoclonal antibodies (targeted therapies) work for people with B-cell non-Hodgkin lymphoma in real-world Italian clinics. It helps doctors learn more about how these treatments affect patients in everyday care.
Viagrande, CataniaAges 18 years+ - NCT06058234Recruiting
Tracking Alzheimer’s treatment for Medicare patients in early stages
This study tracks how well a certain type of Alzheimer’s treatment works for people on Medicare who are in the early stages of the disease. The goal is to collect real-world information about the drug’s benefits and risks.
Baltimore, MarylandAges Any age - NCT06071897RecruitingPhase 3
Chemo-immunotherapy for high-risk neuroblastoma
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
MoscowAges 1.5 years–18 years - NCT06090266RecruitingPhase 1/Phase 2
Study of OR502 alone and with other cancer treatments
This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.
Austin, TexasAges 18 years+ - NCT06121700RecruitingPhase 2
Chemoimmunotherapy and radiation before surgery for limited spread stomach cancer
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
ShanghaiAges 18–75 - NCT06123884RecruitingPhase 2/Phase 3
BAT1308 plus chemotherapy for PD-L1-positive cervical cancer
This clinical trial tests a new combination therapy (BAT1308 plus chemotherapy, with or without Avastin) for women with advanced cervical cancer that is PD-L1-positive and has not been previously treated with systemic therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
Wuhan, HubeiAges 18–70 - NCT06170710RecruitingPhase 2
Immunotherapy after chemoradiation for high-risk head and neck cancer
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
Beijing, Beijing MunicipalityAges 18–70 - NCT06177041RecruitingPhase 3
M108 plus chemo for CLDN18.2-positive stomach cancer
This trial tests a new drug (M108) combined with standard chemotherapy (CAPOX) as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has a specific protein called Claudin 18.2. The goal is to see if adding M108 helps improve outcomes compared to chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06255223RecruitingPhase 2
Radiation therapy plus immunotherapy for advanced kidney cancer
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
Nanjing, JiangsuAges 18–80 - NCT06349044Recruiting
Radiation and immunotherapy with or without probiotics for advanced digestive cancers
This trial tests if adding a probiotic (Lactobacillus rhamnosus M9) to standard radiation and immunotherapy can help people with advanced digestive system cancers. It aims to see if the combination is more effective and safer than the standard approach alone.
Hangzhou, ZhejiangAges 18–75 - NCT06371586RecruitingPhase 2
Neo-Sequence 2: New drug combo for advanced stomach cancer
This trial tests a new treatment plan for advanced stomach cancer using chemotherapy, anti-angiogenesis therapy (to cut off tumor blood supply), and immunotherapy (to help your immune system fight cancer). The goal is to see if this combination works better before surgery.
BeijingAges 18–75 - NCT06425926RecruitingPhase 1/Phase 2
Study of GIM-531 in advanced solid tumors
This study tests a new oral drug, GIM-531, alone and in combination with an anti-PD-1 therapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Scottsdale, ArizonaAges 18 years+
Common questions
- Are there clinical trials studying Monoclonal antibody?
- Yes. Clin2 currently lists 155 recruiting studies that include Monoclonal antibody, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Monoclonal antibody trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Monoclonal antibody an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Monoclonal antibody or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.